Mersana Therapeutics, Inc. (NASDAQ:MRSN) receives consensus recommendation of “Moderate Buy” from analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Your Free Report ) has been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $6.00.

A number of analysts recently weighed in on MRSN shares. Lifesci Capital upgraded Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Robert W. Baird cut their price target on shares of Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th.

Read our latest report on MRSN

Institutional investors are weighing in on Mersana Therapeutics

A number of large investors have recently bought and sold shares of the stock. ClariVest Asset Management LLC purchased a new stake in shares of Mersana Therapeutics in the first quarter valued at $2,114,000. Acadian Asset Management LLC raised its position in shares of Mersana Therapeutics by 166.7% in the first quarter. Acadian Asset Management LLC now owns 468,923 shares of the company’s stock valued at $2,099,000 after purchasing an additional 293,115 shares in the last quarter. Foundations Investment Advisors LLC acquired a new position in shares of Mersana Therapeutics in the fourth quarter valued at approximately $237,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Mersana Therapeutics in the 1st quarter worth about $226,000. Finally, Vanguard Group Inc. boosted its holdings in Mersana Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 6,274,370 shares of the company’s stock valued at $28,109,000 after acquiring an additional 36,782 shares during the last quarter. Institutional investors and hedge funds own 93.92% of the company’s shares.

Mersana Therapeutics Price Performance

Shares of NASDAQ MRSN opened at $1.56 on Friday. The company has a current ratio of 3.51, a quick ratio of 3.51, and a debt-to-equity ratio of 0.72. The stock has a market cap of $190.88 million, a P/E ratio of -1.37 and a beta of 1.55. Mersana Therapeutics has a 12-month low of $1.07 and a 12-month high of $6.28. The stock has a 50-day moving average of $1.83 and a two-hundred-day moving average of $3.03.

Mersana Therapeutics (NASDAQ:MRSN – Get Free Report ) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $2.30 million during the quarter, compared to analysts’ expectations of $8.72 million. Mersana Therapeutics had a negative net margin of 352.01% and a negative return on equity of 260.65%. The company’s quarterly revenue was down 78.3% year over year. In the same quarter last year, the company earned ($0.47) earnings per share. On average, research analysts forecast that Mersana Therapeutics will post -0.6 earnings per share for the current year.

Mersana Therapeutics Company Profile

(Get a free report

Mersana Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops antibody drug conjugates (ADCs) for cancer patients with unmet needs. The company is developing XMT-1660, a Dolasynthen ADC candidate targeting B7-H4; and XMT-2056, an immunosynthesizing ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates.

Recommended articles

Get news and reviews for Mersana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mersana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.